EUR 0.43
(-1.38%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 1000.00 EUR | -50.0% |
2022 | 2000.00 EUR | -99.99% |
2021 | 13.33 Million EUR | 113.24% |
2020 | 6.25 Million EUR | -76.45% |
2019 | 26.55 Million EUR | -64.4% |
2018 | 74.6 Million EUR | 1310.26% |
2017 | 5.29 Million EUR | 7428.85% |
2016 | 70.26 Thousand EUR | 103.89% |
2015 | 34.46 Thousand EUR | 248.47% |
2014 | -23.21 Thousand EUR | -48.77% |
2013 | -15.6 Thousand EUR | 0.0% |
2012 | - EUR | 0.0% |
2011 | - EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 FY | 1.98 Million EUR | 98950.0% |
2023 Q4 | 1001.00 EUR | 0.0% |
2023 Q2 | -16.92 Million EUR | 0.0% |
2022 FY | 2000.00 EUR | -99.99% |
2022 Q4 | -272 Thousand EUR | 0.0% |
2022 Q2 | -281 Thousand EUR | 0.0% |
2021 FY | 13.33 Million EUR | 113.24% |
2021 Q2 | 13.27 Million EUR | 0.0% |
2021 Q4 | -209 Thousand EUR | 0.0% |
2020 Q2 | 6.37 Million EUR | 0.0% |
2020 FY | 6.25 Million EUR | -76.45% |
2020 Q4 | 434 Thousand EUR | 0.0% |
2019 FY | 26.55 Million EUR | -64.4% |
2019 Q1 | 6.63 Million EUR | -73.36% |
2019 Q2 | 6.63 Million EUR | 0.0% |
2019 Q4 | 7.39 Million EUR | 0.0% |
2018 FY | 74.6 Million EUR | 1310.26% |
2018 Q4 | 24.91 Million EUR | 0.0% |
2018 Q1 | 18.65 Million EUR | 252.58% |
2018 Q2 | 37.46 Million EUR | 100.86% |
2017 Q2 | 1.32 Million EUR | 0.0% |
2017 FY | 5.29 Million EUR | 7428.85% |
2017 Q4 | 5.29 Million EUR | 0.0% |
2017 Q1 | 1.32 Million EUR | 2119.58% |
2016 Q1 | 17.56 Thousand EUR | 436.9% |
2016 Q4 | 59.58 Thousand EUR | 0.0% |
2016 FY | 70.26 Thousand EUR | 103.89% |
2016 Q2 | 6886.00 EUR | -60.8% |
2015 Q2 | 39.67 Thousand EUR | 166.07% |
2015 FY | 34.46 Thousand EUR | 248.47% |
2015 Q4 | -5214.00 EUR | -134.97% |
2015 Q3 | 14.91 Thousand EUR | -62.42% |
2015 Q1 | 14.91 Thousand EUR | 344.6% |
2014 Q4 | 3354.00 EUR | 0.0% |
2014 Q3 | - EUR | 100.0% |
2014 Q2 | -11.65 Thousand EUR | 0.0% |
2014 Q1 | - EUR | 100.0% |
2014 FY | -23.21 Thousand EUR | -48.77% |
2013 FY | -15.6 Thousand EUR | 0.0% |
2013 Q4 | -6551.00 EUR | 0.0% |
2013 Q2 | -9051.00 EUR | 0.0% |
2013 Q3 | - EUR | 100.0% |
2013 Q1 | - EUR | 0.0% |
2012 Q3 | - EUR | 0.0% |
2012 FY | - EUR | 0.0% |
2012 Q1 | - EUR | 0.0% |
2012 Q2 | - EUR | 0.0% |
2012 Q4 | - EUR | 0.0% |
2011 Q2 | - EUR | 0.0% |
2011 FY | - EUR | 0.0% |
2011 Q1 | - EUR | 0.0% |
2011 Q4 | - EUR | 0.0% |
2011 Q3 | - EUR | 0.0% |
2010 Q4 | - EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ABIONYX Pharma SA | 618 Thousand EUR | 99.838% |
ABIVAX Société Anonyme | 3.91 Million EUR | 99.974% |
Adocia SA | 1.38 Million EUR | 99.928% |
Aelis Farma SA | 12.35 Million EUR | 99.992% |
Biophytis S.A. | -803 Thousand EUR | 100.125% |
Advicenne S.A. | 1.42 Million EUR | 99.93% |
genOway Société anonyme | 20.1 Million EUR | 99.995% |
IntegraGen SA | 5.01 Million EUR | 99.98% |
Medesis Pharma S.A. | -2.66 Million EUR | 100.038% |
Neovacs S.A. | 29.31 Thousand EUR | 96.589% |
NFL Biosciences SA | -56.06 Thousand EUR | 101.784% |
Plant Advanced Technologies SA | 2.15 Million EUR | 99.954% |
Quantum Genomics Société Anonyme | -1.41 Million EUR | 100.07% |
Sensorion SA | 3.78 Million EUR | 99.974% |
Theranexus Société Anonyme | -4.63 Million EUR | 100.022% |
TME Pharma N.V. | -127 Thousand EUR | 100.787% |
Valbiotis SA | 2.66 Million EUR | 99.963% |
TheraVet SA | -530.79 Thousand EUR | 100.188% |
Valerio Therapeutics Société anonyme | 1.26 Million EUR | 99.921% |
DBV Technologies S.A. | 4.15 Million EUR | 99.976% |
Genfit S.A. | 28.22 Million EUR | 99.996% |
GeNeuro SA | -293.8 Thousand EUR | 100.34% |
Innate Pharma S.A. | -4.12 Million EUR | 100.024% |
Inventiva S.A. | 17.5 Million EUR | 99.994% |
MaaT Pharma SA | 1.65 Million EUR | 99.94% |
MedinCell S.A. | 9.28 Million EUR | 99.989% |
Nanobiotix S.A. | 36.2 Million EUR | 99.997% |
OSE Immunotherapeutics SA | 2.22 Million EUR | 99.955% |
GenSight Biologics S.A. | 3 Million EUR | 99.967% |
Transgene SA | -28.4 Million EUR | 100.004% |
Valneva SE | 52.83 Million EUR | 99.998% |